checkAd
    Startseite > Aktien > COMPASS Pathways > Nachrichten
    COMPASS Pathways Aktie
    6,8000
     
    EUR
    -0,73 %
    -0,0500 EUR
    Letzter Kurs 31.05.24 Tradegate
    6,7500
     
    EUR
    744 STK
    Geldkurs 31.05.24
    6,8500
     
    EUR
    728 STK
    Briefkurs 31.05.24
    ISIN: US20451W1018 · WKN: A2QCDR · SYM: 5Y6 · Großbritannien

    Neueste Nachrichten

    Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
    08.05.24 · globenewswire · COMPASS Pathways
    Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
    08.05.24 · globenewswire · COMPASS Pathways
    Compass Pathways to announce first quarter financial results on May 8, 2024
    03.05.24 · globenewswire · COMPASS Pathways
    Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
    02.05.24 · globenewswire · COMPASS Pathways
    Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
    29.04.24 · globenewswire · COMPASS Pathways
    Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
    01.04.24 · globenewswire · COMPASS Pathways
    Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
    28.03.24 · globenewswire · COMPASS Pathways
    Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 
    29.02.24 · globenewswire · COMPASS Pathways
    Compass Pathways to participate in upcoming TD Cowen investor conference
    26.02.24 · globenewswire · COMPASS Pathways
    Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
    22.02.24 · globenewswire · COMPASS Pathways
    Compass Pathways to participate in upcoming Oppenheimer investor conference
    31.01.24 · globenewswire · COMPASS Pathways
    Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
    16.01.24 · globenewswire · COMPASS Pathways